These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17178829)

  • 1. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
    Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
    Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation.
    Jang KW; Lee JE; Kim SY; Kang MW; Na MH; Lee CS; Song KS; Lim SP
    J Thorac Oncol; 2011 Apr; 6(4):679-87. PubMed ID: 21325980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
    Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
    Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
    Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
    J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
    Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
    Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
    Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
    Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
    Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
    J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP8 modulates ubiquitination of LRIG1 for Met degradation.
    Oh YM; Lee SB; Choi J; Suh HY; Shim S; Song YJ; Kim B; Lee JM; Oh SJ; Jeong Y; Cheong KH; Song PH; Kim KA
    Sci Rep; 2014 May; 4():4980. PubMed ID: 24828152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.
    Gur G; Rubin C; Katz M; Amit I; Citri A; Nilsson J; Amariglio N; Henriksson R; Rechavi G; Hedman H; Wides R; Yarden Y
    EMBO J; 2004 Aug; 23(16):3270-81. PubMed ID: 15282549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
    Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
    Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
    Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased copy number at 3p14 in breast cancer.
    Ljuslinder I; Malmer B; Golovleva I; Thomasson M; Grankvist K; Höckenström T; Emdin S; Jonsson Y; Hedman H; Henriksson R
    Breast Cancer Res; 2005; 7(5):R719-27. PubMed ID: 16168117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.
    Stutz MA; Shattuck DL; Laederich MB; Carraway KL; Sweeney C
    Oncogene; 2008 Sep; 27(43):5741-52. PubMed ID: 18542056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copine-III interacts with ErbB2 and promotes tumor cell migration.
    Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
    Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
    Li Q; Liu B; Chao HP; Ji Y; Lu Y; Mehmood R; Jeter C; Chen T; Moore JR; Li W; Liu C; Rycaj K; Tracz A; Kirk J; Calhoun-Davis T; Xiong J; Deng Q; Huang J; Foster BA; Gokhale A; Chen X; Tang DG
    Nat Commun; 2019 Dec; 10(1):5494. PubMed ID: 31792211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
    Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
    J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.